retatrutide glp-1 gip glucagon agonist Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide 10mg Triple Agonist |

Comprehensive quality assurance procedures include analytical verification of identity, purity assessment through high-performance liquid chromatography (HPLC), and batch-specific quality control documentation

A meta-analysis of 45 clinical trials including 52,600 patients found no statistically significant increased risk of thyroid cancer in GLP-1 receptor agonist users

Although the "PD1and LAG3" combination therapy faced setbacks in MSS mCRC, BMS has stated that research on this combination therapy for treating other types of tumors will proceed as planned

What Are the Side Effects of Retatrutide

A triple-receptor agonist peptide studied across body weight regulation, glycaemic control, and metabolic research

Data availability The datasets utilized and/or analyzed in this study are available from the corresponding author upon reasonable request